drugset / Trial / NCT00863941

A Relative Bioavailability Study of Bupropion XL 150 mg Tablets Under Fasting Conditions

NCT00863941

Phase 1 Completed 28 enrolled Actavis Inc.
RandomizedCrossoverOpen-label

Summary

To compare the rate and extent of absorption of Abrika Bupropion 150 mg XL Tablet to that of Wellbutrin XL® 150 mg Tablet after a single, one-tablet dose in fasted subjects.

Timeline

Start
2004-06
Primary completion
2004-07
Completion
2004-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupropion Small molecule 150 mg

Indications

No indication recorded.